CXCL12 and neoplasm: A monocyte‐derived subpopulation of STAB1+TREM2high lipid‐associated macrophages (LAM) expanded in patients resistant to immune checkpoint blockade (ICB) therapy; this LAM subpopulation is immunosuppressive and acquires tumor‐promoting capacity upon recruitment to the tumor site via the cancer‐associated fibroblast (CAF)‐driven CXCL12–CXCR4 axis, which supports an immunosuppressive microenvironment [162].